Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA:688796)

Revenue by Product

Financials in millions HKD. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Animal Models Selling	421.99M
Animal Models Selling Growth	39.99%
Antibody Development	344.56M
Antibody Development Growth	77.30%
Pre-clinical Pharmacology and Efficacy Evaluation	217.92M
Pre-clinical Pharmacology and Efficacy Evaluation Growth	1.97%
Gene-editing	78.15M
Gene-editing Growth	-4.84%
Other	415.26K
Other Growth	-27.17%
Other	415.26K
Other Growth	-27.17%

Revenue by Geography

Financials in millions HKD. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Other	182.00M
Other Growth	53.74%
United States	536.02M
United States Growth	61.07%
China	345.00M
China Growth	1.17%
Other	182.00M
Other Growth	53.74%